Skip Navigation


Annals of Oncology Advance Access originally published online on February 13, 2008
Annals of Oncology 2008 19(3):405; doi:10.1093/annonc/mdn028
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/3/405    most recent
mdn028v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Survival outcomes of taxanes in breast cancer
 
Despite the increased number of active agents, single-agent taxane therapy remains one of the standard treatments for metastatic breast cancer. Paclitaxel and docetaxel share similar chemical structures and anti-tumor activities, but differ in non-hematologic toxicity profiles. Since patients recruited to clinical trials often have better performance status, Vu et al. [pp. 461–464] compared the overall survival in patients treated with single-agent paclitaxel or docetaxel . . . [Full Text of this Article]


   KRAS in cetuximab-treated colorectal cancer
 

   Toll-like receptors in gastric lymphomas
 

   HSP90 in melanoma
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation
T. Vu, S. Ellard, C. H. Speers, S. C. M. Taylor, M. L. de Lemos, F. Hu, K. Kuik, and I. A. Olivotto
Ann Oncol 2008 19: 461-464. [Abstract] [FREE Full Text]  

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock, H. Piessevaux, J. De Schutter, M. Janssens, G. De Hertogh, N. Personeni, B. Biesmans, J.-L. Van Laethem, M. Peeters, Y. Humblet, E. Van Cutsem, and S. Tejpar
Ann Oncol 2008 19: 508-515. [Abstract] [FREE Full Text]  

Gastric extranodal marginal zone B-cell lymphomas of MALT type exclusively express toll-like receptor 4 in contrast to other lymphomas infiltrating the stomach
P. Adam, B. Schmausser, M. Göbeler-Kolve, H. K. Müller-Hermelink, and M. Eck
Ann Oncol 2008 19: 566-569. [Abstract] [FREE Full Text]  

HSP90 as a marker of progression in melanoma
M. M. McCarthy, E. Pick, Y. Kluger, B. Gould-Rothberg, R. Lazova, R. L. Camp, D. L. Rimm, and H. M. Kluger
Ann Oncol 2008 19: 590-594. [Abstract] [FREE Full Text]